SEC Form 4 · accession 0001209191-17-057320
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, COO
Period of report
Oct 16, 2017
Accepted (ET)
Oct 18, 2017 · 5:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 16, 2017 | M | 2,125 | $96.87 | A | 118,013 | D | |
| Common StockF2,F3 | Oct 16, 2017 | S | 200 | $154.01 | D | 117,813 | D | |
| Common StockF3,F4 | Oct 16, 2017 | S | 875 | $155.03 | D | 116,938 | D | |
| Common StockF3,F5 | Oct 16, 2017 | S | 850 | $156.24 | D | 116,088 | D | |
| Common StockF3,F6 | Oct 16, 2017 | S | 200 | $157.07 | D | 115,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F7 | $96.87 | Oct 16, 2017 | M | 2,125 | D | — | Jul 14, 2024 | Common Stock | 2,125 | 6,375 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $154.01 (range $153.58 to 154.43).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $155.03 (range $154.75 to $155.52).
- F5Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.86 to $156.73).
- F6Open market sales reported on this line occurred at a weighted average price of $157.07 (range $156.96 to $157.17).
- F7The option vests in 16 quarterly installments from 7/15/2014.